Introduction

UnitedHealth Group has faced a difficult stretch on Wall Street, with its shares falling roughly 14% over the last three months. Amid that decline, investment firm TD Cowen is stepping in with a more optimistic view, upgrading the health insurer and pointing to a potential rebound driven by its care services division.

What Happened

TD Cowen moved UnitedHealth to a "buy" rating from "hold" and lifted its share price target to $455 from $402. Based on recent trading levels, the new target implies roughly 38% upside. Analyst Ryan Langston cited a credible path to mid-to-high-teens earnings per share growth through at least 2028. The firm pointed to Medicare Advantage benefit design, a recovery at Optum Health, and improvements in commercial and dual-eligible markets as key drivers.

The upgrade arrives after the Centers for Medicare & Medicaid Services introduced a proposed anti-fraud rule aimed at Medicare and Medicare Advantage programs. That rule initially raised concerns about added scrutiny for insurers like UnitedHealth, though TD Cowen does not expect it to derail the company's broader momentum.

Why This Matters

UnitedHealth is one of the largest health insurers in the United States, and its performance often serves as a barometer for the broader healthcare sector. The stock's recent slide reflects mounting policy headwinds, particularly around government-funded insurance programs. TD Cowen's positive stance suggests that at least one major analyst believes the worst of the regulatory uncertainty may be priced in, especially given the strength of UnitedHealth's patient care and pharmacy businesses.

Key Takeaways

  • TD Cowen upgraded UnitedHealth to "buy" from "hold."
  • The price target was raised to $455 from $402, implying about 38% upside.
  • Shares are down approximately 14% over the past three months.
  • The analyst sees mid-to-high-teens EPS growth through at least 2028.
  • Optum Health margin expansion and Optum Insight's AI products are highlighted as areas to watch.
  • Of 28 analysts tracked by LSEG, 25 rate the stock a buy or strong buy.

Conclusion

While regulatory developments around Medicare Advantage deserve close attention, TD Cowen's upgrade signals confidence in UnitedHealth's underlying businesses. Investors will likely watch Optum Health's profit margins and the rollout of AI-driven tools at Optum Insight for confirmation that the recovery is taking hold. For now, the consensus on Wall Street remains largely favorable, with a clear majority of covering analysts recommending the stock.